Bio-Techne Cp Cmn (TECH) 113.78 $TECH
Techne Has Returned 29.4% Since SmarTrend Recommendation (TECH)
Comtex SmarTrend(R) - 11 mins ago
SmarTrend identified an Uptrend for Techne (NASDAQ:TECH) on February 2nd, 2016 at $87.91. In approximately 6 months, Techne has returned 29.43% as of today's recent price of $113.78.
TECH: 113.78 (+1.36)
Bio-Techne Corporation Completed its Acquisition of Advanced Cell Diagnostics
PR Newswire - Mon Aug 01, 4:27PM CDT
Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Advanced Cell Diagnostics of Newark, CA. This represents the 9th acquisition for Bio-Techne in the last three years. With these acquisitions, Minneapolis-based Bio-Techne has grown from approximately 650 employees in 2013 to nearly 1,700 staff worldwide and has expanded its global reach with subsidiaries in every major geographic market. Organically, we continue to develop and launch in excess of 1,500 new products to market on a yearly basis which enable researchers to address new and more complex questions in the life science field. This latest acquisition of ACD is consistent with our strategic plan, which includes both organic growth and acquisitions that fill portfolio gaps.
TECH: 113.78 (+1.36)
Uptrend Call Working As Techne Stock Rises 26.5% (TECH)
Comtex SmarTrend(R) - Fri Jul 15, 1:25PM CDT
SmarTrend identified an Uptrend for Techne (NASDAQ:TECH) on February 2nd, 2016 at $87.91. In approximately 5 months, Techne has returned 26.46% as of today's recent price of $111.17.
TECH: 113.78 (+1.36)
Bio-Techne Announces Agreement To Acquire Advanced Cell Diagnostics
PR Newswire - Wed Jul 06, 4:37PM CDT
Bio-Techne Corporation (NASDAQ: TECH) announced today that it has agreed to acquire Advanced Cell Diagnostics (ACD) for $250 million in cash plus contingent consideration of $75 million due upon the achievement of certain milestones. The transaction is expected to close on or about August 1, 2016, with closing subject to the satisfaction of customary closing conditions. The transaction will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition.
TECH: 113.78 (+1.36)
Bio-Techne (TECH) Set to Acquire Space Import-Export
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 8:37AM CDT
Bio-Techne Corporation (TECH) plans to acquire Space Import-Export, an Italy-based distribution company in the Life Sciences space, for an undisclosed sum.
FCSC: 1.02 (-0.07), ANIP: 61.06 (+0.46), CYTR: 0.60 (-0.05), TECH: 113.78 (+1.36)
Techne Up 28.4% Since SmarTrend Uptrend Call (TECH)
Comtex SmarTrend(R) - Wed Jun 08, 1:04AM CDT
SmarTrend identified an Uptrend for Techne (NASDAQ:TECH) on February 2nd, 2016 at $87.91. In approximately 4 months, Techne has returned 28.45% as of today's recent price of $112.92.
TECH: 113.78 (+1.36)
Watch for Techne to Potentially Pullback After Gaining 2.36% Yesterday
Comtex SmarTrend(R) - Fri May 27, 3:18PM CDT
Techne (NASDAQ:TECH) traded in a range yesterday that spanned from a low of $106.43 to a high of $109.93. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $108.18 on volume of 111,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TECH: 113.78 (+1.36)
Techne Shares Up 19.6% Since SmarTrend's Buy Recommendation (TECH)
Comtex SmarTrend(R) - Tue May 24, 1:28AM CDT
SmarTrend identified an Uptrend for Techne (NASDAQ:TECH) on February 2nd, 2016 at $87.91. In approximately 4 months, Techne has returned 19.55% as of today's recent price of $105.10.
TECH: 113.78 (+1.36)
TrovaGene (TROV) Q1 Loss Wider than Expected, Stock Gains
Zacks Equity Research - Zacks Investment Research - Wed May 11, 7:16AM CDT
TrovaGene Inc (TROV) reported adjusted loss of 36 cents per share in the first quarter of 2016, wider than the year-ago loss of 33 cents.
TROV: 5.58 (-0.05), TECH: 113.78 (+1.36), EXAC: 27.20 (+0.17), NVRO: 82.34 (-0.36)
Bio-Techne (TECH): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:38AM CDT
Are you a technical investor? If so, it may be time to consider Bio-Techne Corp. (TECH) for your portfolio
TECH: 113.78 (+1.36)
Bio-Techne Corporation Acquires Access to B-MoGen Biotechnologies' Gene Editing Technology
PR Newswire - Wed May 04, 5:00AM CDT
Bio-Techne Corporation (NASDAQ: TECH) and B-MoGen Biotechnologies, Inc. announced today that Bio-Techne has made a seed investment in B-MoGen and the parties have entered into collaboration agreement which gives Bio-Techne access to gene editing technology.
TECH: 113.78 (+1.36)
Upgrade Alert for Techne (TECH)
Comtex SmarTrend(R) - Wed May 04, 3:13AM CDT
Techne (NASDAQ:TECH) was upgraded from Neutral to Buy at Janney Montgomery today. The stock closed yesterday at $100.55 on volume of 595,000 shares, above average daily volume of 231,000. Techne Corporation, through Research and Diagnostic Systems, Inc., manufactures biological products. The Company also, through R&D Systems Europe, Ltd., distributes biotechnology products.
TECH: 113.78 (+1.36)
Bio-Techne Releases Third Quarter Fiscal 2016 Results
PR Newswire - Tue May 03, 6:00AM CDT
Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2016.
TECH: 113.78 (+1.36)
Bio-Techne Declares Dividend
PR Newswire - Tue May 03, 6:00AM CDT
Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2016. The quarterly dividend will be payable May 27, 2016 to all common shareholders of record on May 13, 2016. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
TECH: 113.78 (+1.36)
Bio-Techne To Host Conference Call On May 3, 2016 To Announce Third Quarter Financial Results
PR Newswire - Mon Apr 11, 3:00PM CDT
Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, May 3, 2016, at 8:00 a.m. CDT to review third quarter fiscal 2016 financial results.
TECH: 113.78 (+1.36)
Zacks Investment Ideas feature highlights: Tech Data, Johnson Outdoor, Central Garden and Delta Apparel
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 8:30AM CDT
Zacks Investment Ideas feature highlights: Tech Data, Johnson Outdoor, Central Garden and Delta Apparel
DLA: 22.81 (-1.08), CENT: 24.36 (+0.10), TECH: 113.78 (+1.36), JOUT: 29.73 (-0.72)
Bio-Techne Buys Zephyrus, Boosts Protein Platforms Division
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 8:20AM CDT
Bio-Techne Corp (TECH) recently acquired Zephyrus Biosciences, which will be integrated into the former's Protein Platforms Division.
BPMC: 22.11 (unch), TECH: 113.78 (+1.36), AMAG: 27.02 (+0.49), ANIK: 50.64 (+0.72)
Bio-Techne Corporation Agrees to Acquire Zephyrus Biosciences, Inc.
PR Newswire - Mon Mar 21, 9:34AM CDT
Bio-Techne Corporation (NASDAQ: TECH) announced today that it has completed the acquisition of Zephyrus Biosciences. Zephyrus Biosciences will be integrated into the Protein Platforms Division of Bio-Techne.
TECH: 113.78 (+1.36)
Techne Has Returned 29.4% Since SmarTrend Recommendation (TECH)
Comtex SmarTrend(R) - 11 mins ago
SmarTrend identified an Uptrend for Techne (NASDAQ:TECH) on February 2nd, 2016 at $87.91. In approximately 6 months, Techne has returned 29.43% as of today's recent price of $113.78.
TECH: 113.78 (+1.36)
Bio-Techne Corporation Completed its Acquisition of Advanced Cell Diagnostics
PR Newswire - Mon Aug 01, 4:27PM CDT
Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Advanced Cell Diagnostics of Newark, CA. This represents the 9th acquisition for Bio-Techne in the last three years. With these acquisitions, Minneapolis-based Bio-Techne has grown from approximately 650 employees in 2013 to nearly 1,700 staff worldwide and has expanded its global reach with subsidiaries in every major geographic market. Organically, we continue to develop and launch in excess of 1,500 new products to market on a yearly basis which enable researchers to address new and more complex questions in the life science field. This latest acquisition of ACD is consistent with our strategic plan, which includes both organic growth and acquisitions that fill portfolio gaps.
TECH: 113.78 (+1.36)
Uptrend Call Working As Techne Stock Rises 26.5% (TECH)
Comtex SmarTrend(R) - Fri Jul 15, 1:25PM CDT
SmarTrend identified an Uptrend for Techne (NASDAQ:TECH) on February 2nd, 2016 at $87.91. In approximately 5 months, Techne has returned 26.46% as of today's recent price of $111.17.
TECH: 113.78 (+1.36)
Bio-Techne Announces Agreement To Acquire Advanced Cell Diagnostics
PR Newswire - Wed Jul 06, 4:37PM CDT
Bio-Techne Corporation (NASDAQ: TECH) announced today that it has agreed to acquire Advanced Cell Diagnostics (ACD) for $250 million in cash plus contingent consideration of $75 million due upon the achievement of certain milestones. The transaction is expected to close on or about August 1, 2016, with closing subject to the satisfaction of customary closing conditions. The transaction will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne expects to obtain prior to the closing of the acquisition.
TECH: 113.78 (+1.36)
Bio-Techne (TECH) Set to Acquire Space Import-Export
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 8:37AM CDT
Bio-Techne Corporation (TECH) plans to acquire Space Import-Export, an Italy-based distribution company in the Life Sciences space, for an undisclosed sum.
FCSC: 1.02 (-0.07), ANIP: 61.06 (+0.46), CYTR: 0.60 (-0.05), TECH: 113.78 (+1.36)
Techne Up 28.4% Since SmarTrend Uptrend Call (TECH)
Comtex SmarTrend(R) - Wed Jun 08, 1:04AM CDT
SmarTrend identified an Uptrend for Techne (NASDAQ:TECH) on February 2nd, 2016 at $87.91. In approximately 4 months, Techne has returned 28.45% as of today's recent price of $112.92.
TECH: 113.78 (+1.36)
Watch for Techne to Potentially Pullback After Gaining 2.36% Yesterday
Comtex SmarTrend(R) - Fri May 27, 3:18PM CDT
Techne (NASDAQ:TECH) traded in a range yesterday that spanned from a low of $106.43 to a high of $109.93. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $108.18 on volume of 111,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TECH: 113.78 (+1.36)
Techne Shares Up 19.6% Since SmarTrend's Buy Recommendation (TECH)
Comtex SmarTrend(R) - Tue May 24, 1:28AM CDT
SmarTrend identified an Uptrend for Techne (NASDAQ:TECH) on February 2nd, 2016 at $87.91. In approximately 4 months, Techne has returned 19.55% as of today's recent price of $105.10.
TECH: 113.78 (+1.36)
TrovaGene (TROV) Q1 Loss Wider than Expected, Stock Gains
Zacks Equity Research - Zacks Investment Research - Wed May 11, 7:16AM CDT
TrovaGene Inc (TROV) reported adjusted loss of 36 cents per share in the first quarter of 2016, wider than the year-ago loss of 33 cents.
TROV: 5.58 (-0.05), TECH: 113.78 (+1.36), EXAC: 27.20 (+0.17), NVRO: 82.34 (-0.36)
Bio-Techne (TECH): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:38AM CDT
Are you a technical investor? If so, it may be time to consider Bio-Techne Corp. (TECH) for your portfolio
TECH: 113.78 (+1.36)
Bio-Techne Corporation Acquires Access to B-MoGen Biotechnologies' Gene Editing Technology
PR Newswire - Wed May 04, 5:00AM CDT
Bio-Techne Corporation (NASDAQ: TECH) and B-MoGen Biotechnologies, Inc. announced today that Bio-Techne has made a seed investment in B-MoGen and the parties have entered into collaboration agreement which gives Bio-Techne access to gene editing technology.
TECH: 113.78 (+1.36)
Upgrade Alert for Techne (TECH)
Comtex SmarTrend(R) - Wed May 04, 3:13AM CDT
Techne (NASDAQ:TECH) was upgraded from Neutral to Buy at Janney Montgomery today. The stock closed yesterday at $100.55 on volume of 595,000 shares, above average daily volume of 231,000. Techne Corporation, through Research and Diagnostic Systems, Inc., manufactures biological products. The Company also, through R&D Systems Europe, Ltd., distributes biotechnology products.
TECH: 113.78 (+1.36)
Bio-Techne Releases Third Quarter Fiscal 2016 Results
PR Newswire - Tue May 03, 6:00AM CDT
Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2016.
TECH: 113.78 (+1.36)
Bio-Techne Declares Dividend
PR Newswire - Tue May 03, 6:00AM CDT
Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2016. The quarterly dividend will be payable May 27, 2016 to all common shareholders of record on May 13, 2016. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
TECH: 113.78 (+1.36)
Bio-Techne To Host Conference Call On May 3, 2016 To Announce Third Quarter Financial Results
PR Newswire - Mon Apr 11, 3:00PM CDT
Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, May 3, 2016, at 8:00 a.m. CDT to review third quarter fiscal 2016 financial results.
TECH: 113.78 (+1.36)
Zacks Investment Ideas feature highlights: Tech Data, Johnson Outdoor, Central Garden and Delta Apparel
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 8:30AM CDT
Zacks Investment Ideas feature highlights: Tech Data, Johnson Outdoor, Central Garden and Delta Apparel
DLA: 22.81 (-1.08), CENT: 24.36 (+0.10), TECH: 113.78 (+1.36), JOUT: 29.73 (-0.72)
Bio-Techne Buys Zephyrus, Boosts Protein Platforms Division
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 8:20AM CDT
Bio-Techne Corp (TECH) recently acquired Zephyrus Biosciences, which will be integrated into the former's Protein Platforms Division.
BPMC: 22.11 (unch), TECH: 113.78 (+1.36), AMAG: 27.02 (+0.49), ANIK: 50.64 (+0.72)
Bio-Techne Corporation Agrees to Acquire Zephyrus Biosciences, Inc.
PR Newswire - Mon Mar 21, 9:34AM CDT
Bio-Techne Corporation (NASDAQ: TECH) announced today that it has completed the acquisition of Zephyrus Biosciences. Zephyrus Biosciences will be integrated into the Protein Platforms Division of Bio-Techne.
TECH: 113.78 (+1.36)
